General Information of DTT (ID: TT7HQD0)

DTT Name C-C chemokine receptor type 4 (CCR4) DTT Info
Gene Name CCR4

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
1 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Mogamulizumab DMISH0Z Mycosis fungoides 2B01 Approved [1]
------------------------------------------------------------------------------------
4 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
RPT193 DMZJ0N3 Asthma CA23 Phase 2 [2]
FLX475 DMI7S39 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [3]
ATLCAR.CD30.CCR4 cells DM3IPSX Immune System disease 4A01-4B41 Phase 1 [4]
GSK-2239633 DMUNVXR Asthma CA23 Phase 1 [5]
------------------------------------------------------------------------------------
1 Preclinical Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
AZD-1678 DMY7R3X Asthma CA23 Preclinical [6]
------------------------------------------------------------------------------------
16 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
4-isopropyl-N-(naphthalen-1-yl)thiazol-2-amine DMW1T93 Discovery agent N.A. Investigative [7]
4-methyl-N-(naphthalen-1-yl)thiazol-2-amine DMFRASQ Discovery agent N.A. Investigative [7]
4-tert-butyl-N-(2-isopropylphenyl)thiazol-2-amine DMDWRE5 Discovery agent N.A. Investigative [7]
4-tert-butyl-N-(naphthalen-1-yl)oxazol-2-amine DM5U6ZW Discovery agent N.A. Investigative [7]
4-tert-butyl-N-(naphthalen-1-yl)thiazol-2-amine DMBUZ75 Discovery agent N.A. Investigative [7]
4-tert-butyl-N-m-tolylthiazol-2-amine DM9K27Q Discovery agent N.A. Investigative [7]
4-tert-butyl-N-o-tolylthiazol-2-amine DMJQFD5 Discovery agent N.A. Investigative [7]
4-tert-butyl-N-phenylthiazol-2-amine DM5CPBK Discovery agent N.A. Investigative [7]
AT-008 DMODLPS Autoimmune diabetes 5A10 Investigative [5]
C-014C DMD7OQA Discovery agent N.A. Investigative [8]
N-(4-tert-butylthiazol-2-yl)-1H-indol-4-amine DMFUBQ8 Discovery agent N.A. Investigative [7]
N-(4-tert-butylthiazol-2-yl)isoquinolin-5-amine DMMUX86 Discovery agent N.A. Investigative [7]
N-(4-tert-butylthiazol-2-yl)quinolin-5-amine DMBMAKG Discovery agent N.A. Investigative [7]
N-(naphthalen-1-yl)-4-neopentylthiazol-2-amine DMW378C Discovery agent N.A. Investigative [7]
N-(naphthalen-1-yl)-4-phenylthiazol-2-amine DMFZPCD Discovery agent N.A. Investigative [7]
RS-1748 DM9D8XC Asthma CA23 Investigative [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 Investigative Drug(s)
Molecule Interaction Atlas

References

1 Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma. Curr Opin Mol Ther. 2010 Dec;12(6):770-9.
2 ClinicalTrials.gov (NCT05399368) A Phase 2 Study to Evaluate the Efficacy and Safety of RPT193 as Monotherapy in Adults With Moderate-to-Severe Atopic Dermatitis. U.S.National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT03602157) Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 61).
6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030818)
7 Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3.
8 Discovery of potent CCR4 antagonists: Synthesis and structure-activity relationship study of 2,4-diaminoquinazolines. Bioorg Med Chem. 2008 Jul 15;16(14):7021-32.